Schering-Plough has received FDA approval for NOXAFIL (posaconazole) Oral Suspension for prevention of invasive Aspergillus and Candida infections in patients 13 years of age and older who are at high risk of developing these infections due to being severely immunocompromised, such as hematopoietic stem cell transplant (HSCT) recipients with graft-versus-host disease (GVHD) or those with hematologic malignancies with prolonged neutropenia from chemotherapy. NOXAFIL is a novel triazole antifungal agent discovered and developed by Schering-Plough Research Institute.
